Managing complicated Crohn's disease in children and adolescents (Q36331225)

13 August 2017

1 reference

title

Managing complicated Crohn's disease in children and adolescents (English)

1 reference

13 August 2017

0 references

1 reference

2

Robert N Baldassano

1 reference

13 August 2017

Matjaz Homan

1

1 reference

PubMed ID

16327836

13 August 2017

Petar Mamula

series ordinal

3

1 reference

PubMed ID

16327836

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

Nature Reviews Gastroenterology & Hepatology

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

12

1 reference

13 August 2017

572-579

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpgasthep0338

13 August 2017

0 references

cites work

Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in wisconsin: a statewide population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Inflammatory bowel disease in early childhood and adolescence: special considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Growth and puberty in chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Vertebral compression fractures in pediatric patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Risk factors for low bone mineral density in children and young adults with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Management of growth failure in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Meta-analysis of enteral nutrition as a primary treatment of active crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Methotrexate: first-line or second-line immunomodulator?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Infliximab treatment of rheumatoid arthritis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Treatment of inflammatory bowel disease in childhood: best available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Infliximab therapy in pediatric Crohn's pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Long term safety of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

Inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Inflammatory bowel disease in children 5 years of age and younger

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Nutritional issues in pediatric inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Growth, body composition, and nutritional status in children and adolescents with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Therapy with recombinant growth hormone in children with Crohn disease and growth failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Methotrexate in patients with Crohn's disease after 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

The bioavailability of oral methotrexate in children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Response to infliximab is related to disease duration in paediatric Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Infliximab in Crohn's disease: first anniversary clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

CDP571, a Humanized Anti-Tumor Necrosis Factor-α Monoclonal Antibody in Pediatric Crohn’s Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0338

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0338

1 reference

13 August 2017

1 reference

PubMed ID

16327836